Katrien De Bruyckere

What Happens With Adverse Events During 6 Months of Treatment With Selective Serotonin Reuptake Inhibitors?

Koen Demyttenaere, Adelin Albert, P. Mesters et al. · The Journal of Clinical Psychiatry · 2005 · 36 citations

Pharmacy, Pharmacotherapy, Psychiatry +17

Safety and tolerability of atomoxetine in treatment of attention deficit hyperactivity disorder in adult patients: An integrated analysis of 15 clinical trials

Angelo Camporeale, Vibeke Porsdal, Katrien De Bruyckere et al. · Journal of Psychopharmacology · 2014 · 28 citations

Medicine, Pharmacology, Pharmacotherapy +13

Long-Term Quality-of-Life and Functioning Comparison of Atomoxetine Versus Other Standard Treatment in Pediatric Attention-Deficit/Hyperactivity Disorder

Joaquín Fuentes, Marina Danckaerts, Esther Cardo et al. · Journal of Clinical Psychopharmacology · 2013 · 22 citations

Medicine, Pharmacology, Pharmacotherapy +17

Relationships Between Functional Outcomes and Symptomatic Improvement in Atomoxetine-Treated Adult Patients with Attention-Deficit/Hyperactivity Disorder: Post Hoc Analysis of an Integrated Database

Katrien De Bruyckere, Chris Bushe, Christoph Bartel et al. · CNS Drugs · 2016 · 11 citations

Medicine, Pharmacotherapy, Psychiatry +15

Post Hoc Analysis of Potential Predictors of Response to Atomoxetine for the Treatment of Adults with Attention-Deficit/Hyperactivity Disorder using an Integrated Database

Chris Bushe, Esther Sobanski, David Coghill et al. · CNS Drugs · 2016 · 10 citations

Medicine, Pharmacotherapy, Psychiatry +16